Citadel Advisors
EIDX

Citadel Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Citadel Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,300
Closed -$554K – 10828
2020
Q1 		$554K Buy
+11,300
New +$576K ﹤0.01% 6299

Other funds holding EIDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors's EIDX Position: Q4 2020 in Review

Citadel Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 51,575 shares — an estimated $2.61M sold.

Citadel Advisors first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $2.61M in Q3 2020. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

  • Citadel Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Citadel Advisors sold 51,575 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $2.61M.
  • Citadel Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
  • Citadel Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $2.61M in Q3 2020.
  • 121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.